Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0360319920240060854
Journal of Korean Cancer Research Association
1992 Volume.24 No. 6 p.854 ~ p.859
Clnicopathologic Study of Early Gastric Cancer


Abstract
Despite a decline in the incidence of gastric cancer throughout the world, its incidence and mortality rate is the highest among the all malignancy in Korea.
The prognosis is good in early gastric cancer(EGC) of which the overall 5 year survival rate is 90~95% in the comparision with 15~20% of the advanced gastric cancer, so that early diagnosis and treatment is paramount. Recently, we have achieved
increas
in the detection of early gastric cancer by improved diagnosis principally due to fiberoptic gastroendoscopy with biopsy. This retrospective study was done to evaluate the diagnosis, treatment and prognosis of early gastric cancer.
We found 40 cases(15.5%0 of early gastric cancer among 257 cases of gastric cancer over 7 years.
@ES The results are as follows;
@EN 1) The incidence of E. G. C was 15.6% of all stomach cancer treated during the same period. The incidence of E. G. G is appeared to slightly increased during consecutive 7 years.
2) The male of female ratio was 4:1 and age incidence revealed a greatest prevalance on 5th decade(47.5%).
3) The major blood type was A type937.5%)
4) The most frequent chief complaint was epigastric pain and discomfort.
5) The fiberoptic gastroendoscopy was detected E. G. C more accurately than radiologic examination(60.0%: 32.5%).
6) The most commonest type was IIb+IIc(40.9%) and most prevalent site was antrum, lesser curvature(86.3%).
7) The size of the lesion varied between 0.2cm and 7.0cm and most of them between 1cm and 2cm(47.5%).
8) The cases confined to the mucosa only were 29.9% and other 70.4% were invased to the submucosal layer.
9) Preoperatively, 57.5% of patients underwent endoscopic or radiologic exmination at least two times of E. G. C in comparision with 29.0% of advanced gastric cancer.
KEYWORD
FullTexts / Linksout information
 
Listed journal information
KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø